Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + cisplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Fresenius Kabi USA
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Nab-TPC is a combination chemotherapy regimen consisting of nab-paclitaxel (nanoparticle albumin-bound paclitaxel), cisplatin, and capecitabine. This regimen has been studied as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Nab-paclitaxel is a taxane chemotherapeutic agent formulated with albumin nanoparticles to improve delivery and reduce hypersensitivity reactions compared to conventional paclitaxel. Cisplatin is a platinum-based chemotherapeutic that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and disrupts DNA synthesis. The combination aims to maximize antitumor efficacy through complementary mechanisms of action targeting cell division and DNA replication pathways[3][6][7].
- Other names
- Nab-TPC
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on nab-paclitaxel + cisplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + cisplatin + capecitabine.